Neurology Clinical Trials Market To Reach $19.2 Billion By 2033

October 2026 | Report Format: Electronic (PDF)

Neurology Clinical Trials Market Growth & Trends

The global neurology clinical trials market size is expected to reach USD 19.2 billion by 2033, registering a CAGR of 7.6% from 2026 to 2033, according to a new report by Grand View Research, Inc. This is largely attributed to big pharma companies conducting innovative trials in neurology, increased government funding from the National Institute of Neurological Disorders and Stroke (NINDS), and the high prevalence of neurological disorders worldwide.

Neuroscience continues to receive a healthy investment. For instance, in November 2022, NRG Therapeutics raised Series A funding of USD 18.3 million for the development of mitochondrial therapeutics to treat neurodegenerative ailments such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. The adoption of similar initiatives in the future is expected to support market growth.

A significant number of people worldwide suffer from neurological disorders. For instance, as per the statistics from Parkinson's Foundation, every year 60,000 Americans are diagnosed with PD and more than 10 million people are living with the disease around the world. In terms of Epilepsy, the WHO states that more than 65 million people worldwide are affected by it. The disease is most prevalent in low- and middle-income countries, which account for 80.0% of epilepsy cases. A high prevalence of neurological disorders is expected to boost demand for clinical trials and thus support the market.

Neurology is considered as one of the major areas where clinical trials are conducted. As per the Pharma R&D Annual Review, in 2021, Neurology trials were the third area where clinical trials were majorly focused. The Pharma R&D Annual Review stated that for neurology above 2,900 drugs were under trial and in the year 2022 the number of drugs for clinical studies in the area of neurology accounted for more than 3,200 active drugs. An increasing number of drugs entering clinical trials in the area of neurology are expected to support the market in the post-pandemic period.

key Request a free sample copy or view report summary: Neurology Clinical Trials Market Report

Neurology Clinical Trials Market Report Highlights

By phase: Phase III segment held the largest market share of 42.2% in 2025.The phase I segment is anticipated to grow at the fastest CAGR over the forecast period.
By study design: Interventional segment held the largest market share of 82.4% in 2025.The observational segment is expected to grow at the second-fastest CAGR over the forecast period.
By indication: Alzheimer's disease segment held the largest revenue share of 22.7% in 2025.The Huntington's disease segment is projected to grow at the fastest CAGR over the forecast period.
By value chain: Outsourcing segment held the largest revenue share of 55.7% in 2025.The in-house segment is projected to grow at the second-fastest CAGR over the forecast period.
The North America neurology clinical trials market held the largest revenue share of 46.9% in 2025.

Neurology Clinical Trials Market Segmentation

Grand View Research has segmented global neurology clinical trials market report based on phase, study design, indication, indication by study design, indication by phase, value chain, and region:

Neurology Clinical Trials Phase Outlook (Revenue, USD Million, 2021 - 2033)

Phase I
Phase II
Phase III
Phase IV

Neurology Clinical Trials Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Interventional
Observational
Expanded Access

Neurology Clinical Trials Indication Outlook (Revenue, USD Million, 2021 - 2033)

Alzheimer’s Disease
Depression (MDD)
Parkinson's Disease (PD)
Epilepsy
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease
Muscle Regeneration
Others

Neurology Clinical Trials Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)

Alzheimer’s Disease
- Interventional
- Observational
- Expanded Access
Depression (MDD)
- Interventional
- Observational
- Expanded Access
Parkinson's Disease (PD)
- Interventional
- Observational
- Expanded Access
Epilepsy
- Interventional
- Observational
- Expanded Access
Stroke
- Interventional
- Observational
- Expanded Access
Traumatic Brain Injury (TBI)
- Interventional
- Observational
- Expanded Access
Amyotrophic Lateral Sclerosis (ALS)
- Interventional
- Observational
- Expanded Access
Huntington's Disease
- Interventional
- Observational
- Expanded Access
Muscle Regeneration
- Interventional
- Observational
- Expanded Access
Others
- Interventional
- Observational
- Expanded Access

Neurology Clinical Trials Indication by Phase Outlook (Revenue, USD Million, 2021 - 2033)

Alzheimer’s Disease
- Phase I
- Phase II
- Phase III
- Phase IV
Depression (MDD)
- Phase I
- Phase II
- Phase III
- Phase IV
Parkinson's Disease (PD)
- Phase I
- Phase II
- Phase III
- Phase IV
Epilepsy
- Phase I
- Phase II
- Phase III
- Phase IV
Stroke
- Phase I
- Phase II
- Phase III
- Phase IV
Traumatic Brain Injury (TBI)
- Phase I
- Phase II
- Phase III
- Phase IV
Amyotrophic Lateral Sclerosis (ALS)
- Phase I
- Phase II
- Phase III
- Phase IV
Huntington's Disease
- Phase I
- Phase II
- Phase III
- Phase IV
Muscle Regeneration
- Phase I
- Phase II
- Phase III
- Phase IV
Others
- Phase I
- Phase II
- Phase III
- Phase IV

Neurology Clinical Trials Value Chain Outlook (Revenue, USD Million, 2021 - 2033)

In-house
CROs
Investigator Sites/Clinical Sites

Neurology Clinical Trials Regional Outlook (Revenue, USD Million, 2021 - 2033)

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Asia Pacific
- Japan
- China
- India
- Thailand
- South Korea
- Australia
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- Argentina
- UAE
- Oman
- Qatar